Latest Juvenile Diabetes Research Foundation Stories
A U.S. study has determined type 1 diabetes patients using continuous glucose monitoring improved their HbA1c blood sugar control levels.
New study data presented by the Juvenile Diabetes Research Foundation (JDRF) today at the 44th annual meeting of the European Association for the Study of Diabetes (EASD), showed the use of Continuous Glucose Monitoring (CGM) to be effective in the management of Type 1 Diabetes.
Results of the largest ever Continuous Glucose Monitoring (CGM) study were published online today by the New England Journal of Medicine.
BURGESS HILL, England, September 1 /PRNewswire-FirstCall/ -- With some 20,000 UK children with Type 1 diabetes(i) about to start the new school year, new guidance from the National Institute for Health and Clinical Excellence (NICE) looks set to revolutionise the way children manage their diabetes, granting more freedom and control for their condition, by greater access to insulin pump therapy.
Scientists at the Stanford University School of Medicine are shedding light on how type-1 diabetes begins. Doctors have known the disease is caused by an autoimmune attack on the pancreas, but the exact trigger of the attack has been unclear.
By Stories by MADONNA YANCEY, Courier & Press correspondent Childhood should be a time filled with fun and promise. Not a time of worry and constant medical concerns. For Dana Lobel the wonder of childhood dimmed when her 10-year- old son, Ben, was diagnosed with type 1 diabetes.
EpiVax, Inc, a leader in the field of computational immunology, announced today that it has received a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the National Institutes of Health (NIH), to develop "Epi-13", a novel therapeutic for the prevention and treatment of Type 1 diabetes, a devastating and chronic autoimmune disease that affects three million Americans.
INDIANAPOLIS, June 27 /PRNewswire-FirstCall/ -- Media conference call with Gary Hall Jr.: Monday, June 30, 2:00 PM EDT United States: (800) 553-0327 International: +1 (612) 332-0226 When Olympian Gary Hall Jr.
Osiris Therapeutics has received $2 million in milestone payments from the Juvenile Diabetes Research Foundation for progress made on a Phase II clinical trial evaluating Prochymal, a mesenchymal stem cell therapy, for patients recently diagnosed with type 1 diabetes.
Osiris Therapeutics, Inc.
- A person in a secondary role, specifically the second most important character (after the protagonist).